Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is a condition characterized by a Th2 response, serum eosinophilia, and increased total serum IgE to Aspergillus fumigatus. ABPA occurs in cystic fibrosis (CF) and asthma. Omalizumab is a humanized recombinant monoclonal antibody against IgE...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Asthma Allergy
Main Authors: Ashkenazi, Moshe, Sity, Saray, Sarouk, Ifat, Bar Aluma, Bat El, Dagan, Adi, Bezalel, Yael, Bentur, Lea, De Boeck, Kris, Efrati, Ori
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6016275/
https://ncbi.nlm.nih.gov/pubmed/29950869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JAA.S156049
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki